A Phase II Multi-Center, Randomized, Double-Blind, 24-week, 3-Arm, Parallel Group, Placebo Controlled Study to Investigate RO5285119 Chil/Adol w/ ASD
Project Description:
A Phase II Multi-Center, Randomized, Double-Blind, 24-week, 3-Arm, Parallel Group, Placebo Controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 with Autism Spectrum Disorder (ASD)
Area of Emphasis
Health-Related Activities
Target Audience:
Adults with Disabilities, Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Specific Groups
Primary Target Audience Geographic Descriptor:
National
COVID-19 Related Data:
N/A